PHENOTYPE AND CORECEPTOR USE IN HIV-1 TRANSMISSION

HIV-1 传播中的表型和辅助受体的使用

基本信息

  • 批准号:
    6164190
  • 负责人:
  • 金额:
    $ 11.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-03-01 至 2001-02-28
  • 项目状态:
    已结题

项目摘要

Sexual transmission of human immunodeficiency virus type-I (HIV-1) accounts for the vast majority of new infections worldwide. In most cases, infection occurs as a result of interaction of the virus with CD4+ target cells in the mucosa or sub-epithelium. Interaction of HIV- 1 with CD4 on the cell surface is insufficient for viral entry; however, indicating that additional factors are required for infection to take place. Recent studies have identified several related seven- transmembrane receptors that function as co-factors for viral fusion and entry. Although these co-receptors are utilized by laboratory adapted strains of HIV-1, the extent to which they are used by primary isolates of HIV-1 remains largely unknown. It is of particular importance for vaccine development to determine whether these receptors are used by sexually transmitted strains of HIV-1, whether certain co- receptors are used preferentially and whether this process can be inhibited by the natural ligands for these receptors. The studies outlined in this proposal will directly evaluate the co-receptor requirements of transmitted strains of HIV-1 using a well-characterized panel of primary viruses isolated from patients during acute HIV-1 infection. In preliminary studies, we have evaluated co-receptor use by primary isolates of HIV-1 using a panel of CD4+ cell lines stably expressing each of the known HIV-1 co-receptors. In addition, we have developed a single-cycle complementation assay to determine whether interaction of the viral envelope glycoproteins with each of the HIV-1 co-receptors is sufficient to mediate entry into CD4+ cells. Using these assays, the goals of the proposal are: 1) To determine the primary co-receptor(s) used by transmitted strains of HIV-1 and to correlate co-receptor use with viral phenotype and sensitivity to beta-chemokine blocking. 2) To determine whether primary, transmitted strains of HIV-1 mediate entry into CD4+ cells by interaction of their envelope glycoproteins with specific co-receptors. 3) To determine whether selection for a particular viral phenotype during transmission correlates with co-receptor expression on CD4+ target cells.
人类免疫缺陷病毒i型(HIV-1)的性传播

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ruth Ingrid Connor其他文献

Ruth Ingrid Connor的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ruth Ingrid Connor', 18)}}的其他基金

Lactobacilli as a source of natural microbicides against HIV-1
乳酸杆菌作为抗 HIV-1 天然杀微生物剂的来源
  • 批准号:
    8136239
  • 财政年份:
    2007
  • 资助金额:
    $ 11.62万
  • 项目类别:
Feasibility study of LGG in HIV-exposed, breastfeeding infants in Tanzania.
LGG 在坦桑尼亚暴露于 HIV 的母乳喂养婴儿中的可行性研究。
  • 批准号:
    7497567
  • 财政年份:
    2007
  • 资助金额:
    $ 11.62万
  • 项目类别:
Lactobacilli as a source of natural microbicides against HIV-1
乳酸杆菌作为抗 HIV-1 天然杀微生物剂的来源
  • 批准号:
    7334948
  • 财政年份:
    2007
  • 资助金额:
    $ 11.62万
  • 项目类别:
Lactobacilli as a source of natural microbicides against HIV-1
乳酸杆菌作为抗 HIV-1 天然杀微生物剂的来源
  • 批准号:
    7931066
  • 财政年份:
    2007
  • 资助金额:
    $ 11.62万
  • 项目类别:
Lactobacilli as a source of natural microbicides against HIV-1
乳酸杆菌作为抗 HIV-1 天然杀微生物剂的来源
  • 批准号:
    7939941
  • 财政年份:
    2007
  • 资助金额:
    $ 11.62万
  • 项目类别:
Feasibility study of LGG in HIV-exposed, breastfeeding infants in Tanzania.
LGG 在坦桑尼亚暴露于 HIV 的母乳喂养婴儿中的可行性研究。
  • 批准号:
    7119755
  • 财政年份:
    2007
  • 资助金额:
    $ 11.62万
  • 项目类别:
Lactobacilli as a source of natural microbicides against HIV-1
乳酸杆菌作为抗 HIV-1 天然杀微生物剂的来源
  • 批准号:
    7500866
  • 财政年份:
    2007
  • 资助金额:
    $ 11.62万
  • 项目类别:
Lactic acid bacteria in mucosal defense against HIV-1
乳酸菌在粘膜防御 HIV-1 中的作用
  • 批准号:
    7104531
  • 财政年份:
    2005
  • 资助金额:
    $ 11.62万
  • 项目类别:
Lactic acid bacteria in mucosal defense against HIV-1
乳酸菌在粘膜防御 HIV-1 中的作用
  • 批准号:
    7086805
  • 财政年份:
    2005
  • 资助金额:
    $ 11.62万
  • 项目类别:
PHENOTYPE AND CORECEPTOR USE IN HIV-1 TRANSMISSION
HIV-1 传播中的表型和辅助受体的使用
  • 批准号:
    2667786
  • 财政年份:
    1997
  • 资助金额:
    $ 11.62万
  • 项目类别:

相似海外基金

PROTEIN X-RAY CRYSTALLOGRAPHY: HIV ENVELOPE PROTEIN
蛋白质 X 射线晶体学:HIV 包膜蛋白
  • 批准号:
    7369566
  • 财政年份:
    2005
  • 资助金额:
    $ 11.62万
  • 项目类别:
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN
GP120 和 HIV 包膜蛋白促进疼痛
  • 批准号:
    6188002
  • 财政年份:
    1999
  • 资助金额:
    $ 11.62万
  • 项目类别:
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN
GP120 和 HIV 包膜蛋白促进疼痛
  • 批准号:
    6540025
  • 财政年份:
    1999
  • 资助金额:
    $ 11.62万
  • 项目类别:
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN
GP120 和 HIV 包膜蛋白促进疼痛
  • 批准号:
    2907163
  • 财政年份:
    1999
  • 资助金额:
    $ 11.62万
  • 项目类别:
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN
GP120 和 HIV 包膜蛋白促进疼痛
  • 批准号:
    6612844
  • 财政年份:
    1999
  • 资助金额:
    $ 11.62万
  • 项目类别:
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN
GP120 和 HIV 包膜蛋白促进疼痛
  • 批准号:
    6394025
  • 财政年份:
    1999
  • 资助金额:
    $ 11.62万
  • 项目类别:
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN
GP120 和 HIV 包膜蛋白促进疼痛
  • 批准号:
    6559805
  • 财政年份:
    1999
  • 资助金额:
    $ 11.62万
  • 项目类别:
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN
GP120 和 HIV 包膜蛋白促进疼痛
  • 批准号:
    6211668
  • 财政年份:
    1999
  • 资助金额:
    $ 11.62万
  • 项目类别:
Influence of HIV envelope protein oligomerization on interactions with chemokine receptors.
HIV 包膜蛋白寡聚化对与趋化因子受体相互作用的影响。
  • 批准号:
    nhmrc : 987004
  • 财政年份:
    1998
  • 资助金额:
    $ 11.62万
  • 项目类别:
    CARG - People
Antiviral agents that disrupt the HIV envelope protein function
破坏 HIV 包膜蛋白功能的抗病毒药物
  • 批准号:
    nhmrc : 956047
  • 财政年份:
    1995
  • 资助金额:
    $ 11.62万
  • 项目类别:
    CARG - Research
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了